{"id":"https://openalex.org/W4408819880","doi":"https://doi.org/10.1002/jppr.70003","title":"Therapeutic drug monitoring and pharmacogenomic guided perhexiline therapy in kidney failure requiring haemodialysis: a case study","display_name":"Therapeutic drug monitoring and pharmacogenomic guided perhexiline therapy in kidney failure requiring haemodialysis: a case study","publication_year":2025,"publication_date":"2025-03-25","ids":{"openalex":"https://openalex.org/W4408819880","doi":"https://doi.org/10.1002/jppr.70003"},"language":"en","primary_location":{"id":"doi:10.1002/jppr.70003","doi":"https://doi.org/10.1002/jppr.70003","is_oa":true,"landing_page_url":"https://doi.org/10.1002/jppr.70003","pdf_url":null,"source":{"id":"https://openalex.org/S2765012975","display_name":"Journal of Pharmacy Practice and Research","issn_l":"0310-6810","issn":["0310-6810","1445-937X","2055-2335"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","norway-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Pharmacy Practice and Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1002/jppr.70003","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Harry Ashton","orcid":"https://orcid.org/0009-0001-0576-5091","observed_orcids":["https://orcid.org/0009-0001-0576-5091"]},"institutions":[{"id":"https://openalex.org/I165143802","display_name":"The University of Queensland","ror":"https://ror.org/00rqy9422","country_code":"AU","type":"education","lineage":["https://openalex.org/I165143802"]},{"id":"https://openalex.org/I4388482739","display_name":"Armadale Health Service","ror":"https://ror.org/01nkdyf86","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I2799506148","https://openalex.org/I2800882159","https://openalex.org/I4388446364","https://openalex.org/I4388482739"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Harry Ashton","raw_affiliation_strings":["Armadale Health Service  Perth Australia","School of Pharmacy and Pharmaceutical Sciences University of Queensland  Brisbane Australia","School of Pharmaceutical Sciences University of Queensland  Brisbane Australia"],"raw_orcid":"https://orcid.org/0009-0001-0576-5091","affiliations":[{"raw_affiliation_string":"Armadale Health Service  Perth Australia","institution_ids":["https://openalex.org/I4388482739"]},{"raw_affiliation_string":"School of Pharmacy and Pharmaceutical Sciences University of Queensland  Brisbane Australia","institution_ids":["https://openalex.org/I165143802"]},{"raw_affiliation_string":"School of Pharmaceutical Sciences University of Queensland  Brisbane Australia","institution_ids":["https://openalex.org/I165143802"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102767991","display_name":"Hemant Kulkarni","orcid":"https://orcid.org/0000-0001-6157-2668","observed_orcids":["https://orcid.org/0000-0001-6157-2668"]},"institutions":[{"id":"https://openalex.org/I4388482739","display_name":"Armadale Health Service","ror":"https://ror.org/01nkdyf86","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I2799506148","https://openalex.org/I2800882159","https://openalex.org/I4388446364","https://openalex.org/I4388482739"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Hemant Kulkarni","raw_affiliation_strings":["Armadale Health Service  Perth Australia"],"raw_orcid":"https://orcid.org/0000-0001-6157-2668","affiliations":[{"raw_affiliation_string":"Armadale Health Service  Perth Australia","institution_ids":["https://openalex.org/I4388482739"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2760,"currency":"USD","value_usd":2760},"apc_paid":{"value":2760,"currency":"USD","value_usd":2760},"fwci":0.8801,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.70080723,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":94},"biblio":{"volume":"55","issue":"3","first_page":"244","last_page":"247"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.986299991607666,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.986299991607666,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10291","display_name":"Dialysis and Renal Disease Management","score":0.003100000089034438,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11064","display_name":"Antiplatelet Therapy and Cardiovascular Diseases","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/perhexiline","display_name":"perhexiline","score":0.9980000257492065},{"id":"https://openalex.org/keywords/hemodialysis","display_name":"hemodialysis","score":0.9570000171661377},{"id":"https://openalex.org/keywords/kidney-failure","display_name":"renal failure","score":0.8920000195503235},{"id":"https://openalex.org/keywords/ischemic-heart-disease","display_name":"ischemic heart disease","score":0.9100000262260437},{"id":"https://openalex.org/keywords/therapeutic-drug-monitoring","display_name":"therapeutic drug monitoring","score":0.875},{"id":"https://openalex.org/keywords/pharmacogenomics","display_name":"pharmacogenomics","score":0.9509999752044678},{"id":"https://openalex.org/keywords/cyp2d6","display_name":"CYP2D6","score":0.8859999775886536},{"id":"https://openalex.org/keywords/antianginal-therapy","display_name":"antianginal therapy","score":0.878000020980835},{"id":"https://openalex.org/keywords/refractory-angina","display_name":"refractory angina","score":0.7699999809265137},{"id":"https://openalex.org/keywords/drug-safety-in-renal-impairment","display_name":"drug safety in renal impairment","score":0.6079999804496765}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9779043197631836},{"id":"https://openalex.org/C170734499","wikidata":"https://www.wikidata.org/wiki/Q1152227","display_name":"Pharmacogenomics","level":2,"score":0.6954628825187683},{"id":"https://openalex.org/C2780272996","wikidata":"https://www.wikidata.org/wiki/Q1261151","display_name":"Therapeutic drug monitoring","level":3,"score":0.5758957266807556},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5563220977783203},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.5449137091636658},{"id":"https://openalex.org/C2779541074","wikidata":"https://www.wikidata.org/wiki/Q185643","display_name":"Renal replacement therapy","level":2,"score":0.46045854687690735},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4163581132888794},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3946838974952698}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1002/jppr.70003","doi":"https://doi.org/10.1002/jppr.70003","is_oa":true,"landing_page_url":"https://doi.org/10.1002/jppr.70003","pdf_url":null,"source":{"id":"https://openalex.org/S2765012975","display_name":"Journal of Pharmacy Practice and Research","issn_l":"0310-6810","issn":["0310-6810","1445-937X","2055-2335"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","norway-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Pharmacy Practice and Research","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1002/jppr.70003","doi":"https://doi.org/10.1002/jppr.70003","is_oa":true,"landing_page_url":"https://doi.org/10.1002/jppr.70003","pdf_url":null,"source":{"id":"https://openalex.org/S2765012975","display_name":"Journal of Pharmacy Practice and Research","issn_l":"0310-6810","issn":["0310-6810","1445-937X","2055-2335"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","norway-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Pharmacy Practice and Research","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[],"study_designs":[{"display_name":"Case Report","id":"https://openalex.org/study-designs/case-report"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":10,"referenced_works":["https://openalex.org/W1499896461","https://openalex.org/W2002436590","https://openalex.org/W2137944624","https://openalex.org/W2143651952","https://openalex.org/W2184002524","https://openalex.org/W2751376750","https://openalex.org/W2974932310","https://openalex.org/W3123906508","https://openalex.org/W4246681983","https://openalex.org/W4321483180"],"related_works":["https://openalex.org/W2899084033","https://openalex.org/W2556874318","https://openalex.org/W2151018706","https://openalex.org/W2370955888","https://openalex.org/W1557353121","https://openalex.org/W1966032531","https://openalex.org/W3036044090","https://openalex.org/W2017042860","https://openalex.org/W4245516050","https://openalex.org/W2417275167"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Ischaemic":[2],"heart":[3,112,141],"disease":[4,113,142],"is":[5,34],"a":[6,59,70,239],"leading":[7],"cause":[8],"of":[9,62,86,127,219,241],"morbidity":[10],"and":[11,27,64,81,110,125,168,176,179,187,257],"mortality":[12],"in":[13,36,43,69,83,119,163,199,221,243,259],"haemodialysis":[14,182],"patients,":[15],"yet":[16],"conventional":[17,128],"therapies":[18],"are":[19,249],"often":[20],"precluded":[21],"due":[22],"to":[23,227,251],"increased":[24],"perioperative":[25],"risk":[26],"medication":[28],"contraindications.":[29],"Perhexiline,":[30],"an":[31,98,193],"antianginal":[32,129],"agent,":[33],"contraindicated":[35],"renal":[37],"impairment.":[38],"Research":[39],"has":[40,160],"suggested":[41],"therapy":[42,68,130,240],"kidney":[44,106,222,261],"failure":[45,107,262],"may":[46],"be":[47],"safe,":[48],"but":[49],"these":[50],"studies":[51,248],"excluded":[52],"patients":[53],"requiring":[54,72],"haemodialysis.":[55],"Aim":[56],"We":[57],"describe":[58],"novel":[60],"case":[61],"safe":[63],"effective":[65,203],"long\u2010term":[66,255],"perhexiline":[67,132,220],"patient":[71,201,245],"haemodialysis,":[73],"with":[74,97,121,192,204,213],"treatment":[75],"guided":[76],"by":[77,181],"therapeutic":[78,173],"drug":[79],"monitoring":[80],"interpreted":[82],"the":[84,144,217,260],"context":[85],"pharmacogenomic":[87],"screening.":[88],"Clinical":[89],"Details":[90],"A":[91],"male":[92],"patient,":[93],"aged":[94],"84":[95],"years,":[96],"intermediate":[99,194],"cytochrome":[100],"P450":[101],"2D6":[102],"(CYP2D6)":[103],"metaboliser":[104,196],"phenotype,":[105],"(requiring":[108],"haemodialysis)":[109],"ischaemic":[111,140,229],"(quintuple":[114],"coronary":[115],"artery":[116],"bypass":[117],"grafting":[118],"1999":[120],"multiple":[122],"occluded":[123],"grafts),":[124],"intolerant":[126],"received":[131],"50":[133],"mg,":[134],"twice":[135],"daily,":[136],"for":[137,143],"refractory":[138],"symptomatic":[139],"past":[145],"three":[146],"years.":[147],"[Correction":[148],"added":[149],"on":[150],"28":[151],"April":[152],"2025,":[153],"after":[154,177],"first":[155],"online":[156],"publication:":[157],"Some":[158],"text":[159],"been":[161],"corrected":[162],"this":[164,200,244],"section].":[165],"Outcomes":[166],"Perhexiline":[167],"metabolite":[169],"levels":[170],"remained":[171],"within":[172],"range":[174],"before":[175],"dialysis,":[178],"clearance":[180],"was":[183,202],"negligible.":[184],"Pharmacogenomic":[185],"screening":[186],"hydroxyperhexiline/perhexiline":[188],"ratios":[189],"were":[190],"consistent":[191],"CYP2D6":[195],"phenotype.":[197],"Therapy":[198],"no":[205],"adverse":[206],"events":[207],"identified.":[208],"Conclusion":[209],"This":[210],"case,":[211],"combined":[212],"existing":[214],"literature,":[215],"challenges":[216],"contraindication":[218],"failure.":[223],"Perhexiline's":[224],"unique":[225],"ability":[226],"relieve":[228],"symptoms":[230],"without":[231],"inducing":[232],"intolerable":[233],"blood":[234],"pressure":[235],"reduction":[236],"makes":[237],"it":[238],"interest":[242],"population.":[246,263],"Further":[247],"needed":[250],"definitively":[252],"establish":[253],"its":[254],"safety":[256],"efficacy":[258]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2025-10-10T00:00:00"}